Cagrilintide
Cagrilintide is a long-acting, acylated synthetic analog of the pancreatic satiety hormone amylin, studied for appetite suppression and weight reduction; research protocols typically use 0.25 mg weekly subcutaneously (titrating toward 1.7 mg).
It has been studied primarily for appetite suppression and body-weight reduction in obesity and overweight, as monotherapy and in combination with GLP-1 receptor agonists.
Cagrilintide is a long-acting, lipidated (acylated) synthetic analog of human amylin, the pancreatic hormone co-secreted with insulin that contributes to satiety signaling. Structural modifications, including an N-terminal lipid moiety and a stabilizing ionic lock between residues, extend its half-life to support once-weekly subcutaneous administration in research settings. It is a non-selective agonist at the amylin receptor family (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR) — class B GPCRs in which the calcitonin receptor pairs with receptor activity-modifying proteins (RAMPs) to form the amylin receptors.
Research has characterized its binding mode by cryo-EM and shown that its weight-lowering effects depend on central amylin receptors 1 and 3 in the hindbrain area postrema, where signaling has been associated with reduced food intake and slowed gastric emptying. Cagrilintide is developed by Novo Nordisk and is not FDA-approved; it remains an investigational compound under clinical study (including the CagriSema combination), and outside registered trials it is handled only as a research compound.
In clinical research it has typically been administered as a once-weekly subcutaneous injection using a gradual dose-escalation approach, with reported research doses ranging from roughly 0.3 mg up to 2.4 mg weekly.
Research suggests appetite and weight effects emerge gradually over weeks of sustained weekly dosing rather than acutely, with trial endpoints commonly assessed at 20 to 68 weeks.
It is most commonly studied alongside the GLP-1 receptor agonist semaglutide (the investigational CagriSema combination), reflecting interest in complementary amylin and incretin pathways.
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.